Amryt Pharma plc Operating Income 2011-2026 | AMYT

Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.

Formula

Operating profit = Revenue – Operating expenses

Features of the metric

Evaluates business efficiency
Shows how well the company controls its production and administrative costs.
Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies.
Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.

If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.

Annual Operating Income Amryt Pharma plc

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-38.6 M	-46.5 M	-50.5 M	-18 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-18 M	-50.5 M	-38.4 M

Operating Income of other stocks in the Biotechnology industry

Issuer	Operating Income	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
ARCA biopharma ABIO	-88.1 M	-	1052.0 %	$ 415 M	USA
Processa Pharmaceuticals PCSA	-14 M	$ 2.3	-1.29 %	$ 3.01 M	USA
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
Albireo Pharma ALBO	-123 M	-	-0.23 %	$ 916 M	USA
Aileron Therapeutics ALRN	-65.1 M	-	10.36 %	$ 9.8 M	USA
Genfit SA GNFT	31.8 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Ascendis Pharma A/S ASND	-452 M	$ 220.9	2.49 %	$ 5 B	Danmark
Aptinyx APTX	-62.6 M	-	-39.0 %	$ 4.57 M	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
Amphastar Pharmaceuticals AMPH	140 M	$ 19.57	1.77 %	$ 915 M	USA
Applied Genetic Technologies Corporation AGTC	-17.7 M	-	-	$ 26.5 M	USA
Phathom Pharmaceuticals PHAT	-160 M	$ 10.47	4.08 %	$ 763 M	USA
Ayala Pharmaceuticals AYLA	-37.5 M	-	-	$ 7.46 M	Israel
AgeX Therapeutics AGE	-9.89 M	-	-10.17 %	$ 12.2 K	USA
Acorda Therapeutics ACOR	-265 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	-16.7 M	-	4.01 %	$ 150 M	Canada
BeiGene, Ltd. BGNE	447 M	-	0.49 %	$ 251 B	Cayman-islands
bluebird bio BLUE	-244 M	-	-	$ 546 M	USA
Cara Therapeutics CARA	-121 M	-	-3.03 %	$ 260 M	USA
Adverum Biotechnologies ADVM	-139 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	-24.6 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	-36.3 M	-	-9.65 %	$ 45.9 M	USA
Pliant Therapeutics PLRX	-156 M	$ 1.31	2.34 %	$ 80.4 M	USA
PMV Pharmaceuticals PMVP	-86.2 M	$ 1.37	-1.44 %	$ 72 M	USA
Avenue Therapeutics ATXI	-11.3 M	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	-241 M	$ 1.33	0.76 %	$ 339 M	Britain
Corbus Pharmaceuticals Holdings CRBP	-85.3 M	$ 8.31	1.59 %	$ 111 M	USA
CRISPR Therapeutics AG CRSP	-665 M	$ 47.09	1.42 %	$ 4.23 B	Schweiz
Cyclacel Pharmaceuticals CYCC	-12 M	-	-5.98 %	$ 34.1 M	USA
ChemoCentryx CCXI	-130 M	-	-	$ 3.74 B	USA
Prelude Therapeutics Incorporated PRLD	-105 M	$ 3.26	4.49 %	$ 251 M	USA
Dynavax Technologies Corporation DVAX	-4.12 M	-	-	$ 2.02 B	USA
ProQR Therapeutics N.V. PRQR	-57.2 M	$ 1.58	6.04 %	$ 99.5 M	Niderland
BioDelivery Sciences International BDSI	37.1 M	-	-4.8 %	$ 255 M	USA
Enochian Biosciences ENOB	-189 M	-	-	$ 40.5 M	USA
Aeglea BioTherapeutics AGLE	-210 M	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Palatin Technologies PTN	-17.5 M	$ 21.0	5.79 %	$ 19.5 M	USA
Bellerophon Therapeutics BLPH	-22.4 M	-	-74.18 %	$ 955 K	USA
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
Pulmatrix PULM	-5.17 M	$ 2.12	-1.4 %	$ 7.74 M	USA
Arbutus Biopharma Corporation ABUS	-38.2 M	$ 4.53	5.1 %	$ 868 M	Canada
Homology Medicines FIXX	16.9 M	-	0.77 %	$ 53.4 M	USA